A. Sabzvari

A Phase IVStudyof theSafety andEfficacyofCinnoPar® in Iranian Patients with Osteoporosis

A. Salari, A. Jamshidi, N. Anjidani, 2021 .

A  Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis

A. Salari, A. Jamshidi, N. Anjidani, 2021, Journal of osteoporosis.

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

N. Petrovsky, M. Mardani, P. Tabarsi, 2022, Clinical Microbiology and Infection.

The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases.

Niusha Sharifinejad, H. Hamedifar, G. Azizi, 2021, International immunopharmacology.

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial

N. Petrovsky, M. Mardani, P. Tabarsi, 2022, Clinical Microbiology and Infection.

Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).

V. Shaygannejad, F. Ashtari, Nahid Beladi moghadam, 2024, Multiple sclerosis and related disorders.